HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Targets Sustainable Palm Oil Alternative With $120m Biotech Deal

Executive Summary

Unilever PLC partners with biotechnology company Genomatica to fund and scale plant-based alternatives to palm oil for personal care and cleaning products.

You may also be interested in...



Delaying Price Increases Dragged Down Colgate’s Q1 Results As Supply Costs Continue Climbing

High costs pummeled Q1 results down 17.9% to $559m. Net sales were up 1.5% to $4.39bn, with price hikes made late in quarter driving a 4% increase in organic sales. Hong Kong firm Hawley & Hazel Co., 50% owned by Colgate since 1985, relaunches Chinese name of its Darlie brand oral care line as Haolai.

Unilever's 'Careful' Pricing Strategy Pays Off In Q1

Unilever PLC says pricing is critical to enabling it to continue investing in brands as input cost inflation for the firm in 2022 is expected to reach almost 5bn. The British company increased pricing 8% across its portfolio, which includes skin care brand Dove and vitamin brand Olly, helping drive total underlying sales growth of 7.3% in the first quarter.

Cosmetics Firms Must Scrutinize Supply Chain Amid Growing Reputational Risks

In today’s cosmetics market where manufacturers increasingly are sourcing commodity-based ingredients to answer natural product demand, risk of being linked to social or environmental ills is higher than ever, a Verisk Maplecroft analyst suggests.

Topics

Latest News
UsernamePublicRestriction

Register

RS152644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel